Yorifumi Satou, MD, PhD, is a virologist at Kumamoto University focused on HTLV-1 immunovirology and the pathogenesis of adult T-cell leukemia/lymphoma (ATL). His lab integrates molecular virology with human immunology to explain how persistent retroviral infection rewires T-cell function and drives disease.
A central theme is the antisense gene HBZ. Foundational work in PNAS (2006) and PLoS Path (2011) defined HBZ expression and function, establishing it as a driver of infected-cell persistence and a rational target for immune and therapeutic intervention.
Satou also advanced the concept of intragenic proviral regulation, showing that HTLV-1 uses internal regulatory elements beyond the LTR. Studies in PNAS (2016), Nat Commun (2022), and Nat Microbiol (2025) mapped these programs and linked them to latency, reactivation, and tissue-specific expression—insights now used to quantify and modulate proviral activity in vivo.
Connecting mechanism to disease, his team demonstrated that ATL cells are profoundly activated T cells (JCI, 2021), reframing ATL as a malignancy entwined with chronic T-cell activation and informing immune and exhaustion-targeted therapies.
Satou mentors trainees and collaborates across Japan and internationally, deploying single-cell assays, and spatial profiling to connect proviral control with host immunity. By uniting key mechanisms above, his program charts actionable paths to improved diagnostics and therapies for HTLV-1-associated disease.
Yorifumi Satou, MD, PhD, is a virologist at Kumamoto University focused on HTLV-1 immunovirology and the pathogenesis of adult T-cell leukemia/lymphoma (ATL). His lab integrates molecular virology with human immunology to explain how persistent retroviral infection rewires T-cell function and drives disease.
A central theme is the antisense gene HBZ. Foundational work in PNAS (2006) and PLoS Path (2011) defined HBZ expression and function, establishing it as a driver of infected-cell persistence and a rational target for immune and therapeutic intervention.
Satou also advanced the concept of intragenic proviral regulation, showing that HTLV-1 uses internal regulatory elements beyond the LTR. Studies in PNAS (2016), Nat Commun (2022), and Nat Microbiol (2025) mapped these programs and linked them to latency, reactivation, and tissue-specific expression—insights now used to quantify and modulate proviral activity in vivo.
Connecting mechanism to disease, his team demonstrated that ATL cells are profoundly activated T cells (JCI, 2021), reframing ATL as a malignancy entwined with chronic T-cell activation and informing immune and exhaustion-targeted therapies.
Satou mentors trainees and collaborates across Japan and internationally, deploying single-cell assays, and spatial profiling to connect proviral control with host immunity. By uniting key mechanisms above, his program charts actionable paths to improved diagnostics and therapies for HTLV-1-associated disease.